Status:
UNKNOWN
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Lead Sponsor:
Sungkyunkwan University
Collaborating Sponsors:
Ministry of Food and Drug Safety, Korea
Conditions:
Carcinoma, Non-Small-Cell Lung
Immune-Related Adverse Events
Eligibility:
All Genders
18+ years
Brief Summary
The objective of our study is to assess the risk of immune-related adverse events associated with PD-1 inhibitors use compared to standard chemotherapy use in patients with non small cell lung cancer,...
Detailed Description
This observational, retrospective cohort study will evaluate the risk of immune-related adverse events associated with PD-1 inhibitors use compared to standard chemotherapy use in patients with non sm...
Eligibility Criteria
Inclusion
- Individuals who were diagnosed with lung cancer (ICD-10: C33-C34) between 2017 and 2018.
Exclusion
- Individuals less than 18 years of age
- Individuals received any systemic anticancer therapies in 2007
- Having no records of prescription of PD-1 inhibitors or standard chemotherapy at least once between 2017 and 2018
- Individuals received treatments indicated for small cell lung cancer (etoposide, ifosfamide, irinotecan, belotecan, and topotecan) on or before the first date of standard chemotherapy to restrict study subjects to patients with non small cell lung cancer only.
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
4724 Patients enrolled
Trial Details
Trial ID
NCT04115410
Start Date
July 1 2020
End Date
December 31 2021
Last Update
May 28 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.